Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options.

IF 2.6 Q2 GASTROENTEROLOGY & HEPATOLOGY
Hepatic Medicine : Evidence and Research Pub Date : 2019-01-25 eCollection Date: 2019-01-01 DOI:10.2147/HMER.S169024
Cyriac Abby Philips, Sasidharan Rajesh, Philip Augustine, Guruprasad Padsalgi, Rizwan Ahamed
{"title":"Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options.","authors":"Cyriac Abby Philips,&nbsp;Sasidharan Rajesh,&nbsp;Philip Augustine,&nbsp;Guruprasad Padsalgi,&nbsp;Rizwan Ahamed","doi":"10.2147/HMER.S169024","DOIUrl":null,"url":null,"abstract":"<p><p>Portosystemic shunt (PS) syndrome encompasses a spectrum of disease manifestations ranging from asymptomatic portal hypertension to recurrent and refractory hepatic encephalopathy, ultimately culminating in progressive hepatic failure in patients of cirrhosis and associated large PSs. PSs commonly seen in cirrhosis include splenorenal, gastrorenal, and dilated paraumbilical veins, all of which can present with recurrent or refractory hepatic encephalopathy. In this exhaustive review, we describe the anatomy of PSs, elucidate new theories on their pathophysiology, discuss the clinical implications of PSs in cirrhosis, provide details on different techniques (classical and novel) of shunt embolization, and explore all the pertinent current literature on shunt embolization for refractory and recurrent hepatic encephalopathy, all of which are enumerated with extensive images and illustrations.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"11 ","pages":"23-34"},"PeriodicalIF":2.6000,"publicationDate":"2019-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/HMER.S169024","citationCount":"31","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Medicine : Evidence and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/HMER.S169024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 31

Abstract

Portosystemic shunt (PS) syndrome encompasses a spectrum of disease manifestations ranging from asymptomatic portal hypertension to recurrent and refractory hepatic encephalopathy, ultimately culminating in progressive hepatic failure in patients of cirrhosis and associated large PSs. PSs commonly seen in cirrhosis include splenorenal, gastrorenal, and dilated paraumbilical veins, all of which can present with recurrent or refractory hepatic encephalopathy. In this exhaustive review, we describe the anatomy of PSs, elucidate new theories on their pathophysiology, discuss the clinical implications of PSs in cirrhosis, provide details on different techniques (classical and novel) of shunt embolization, and explore all the pertinent current literature on shunt embolization for refractory and recurrent hepatic encephalopathy, all of which are enumerated with extensive images and illustrations.

门静脉系统分流和难治性肝性脑病:患者选择和当前选择。
门静脉系统分流综合征包括一系列疾病表现,从无症状门静脉高压症到复发性难治性肝性脑病,最终在肝硬化和相关的大门静脉系统分流患者中以进行性肝功能衰竭告终。肝硬化中常见的PSs包括脾肾、胃肾和脐旁静脉扩张,所有这些都可以出现复发性或难治性肝性脑病。在这篇详尽的综述中,我们描述了PSs的解剖结构,阐明了其病理生理学的新理论,讨论了PSs在肝硬化中的临床意义,详细介绍了分流栓塞的不同技术(经典的和新颖的),并探讨了目前关于分流栓塞治疗难治性和复发性肝性脑病的所有相关文献,并列举了大量的图像和插图。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hepatic Medicine : Evidence and Research
Hepatic Medicine : Evidence and Research GASTROENTEROLOGY & HEPATOLOGY-
自引率
0.00%
发文量
15
审稿时长
16 weeks
期刊介绍: Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease Investigation and treatment of hepatic disease Pharmacology of drugs used for the treatment of hepatic disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered. As of 1st April 2019, Hepatic Medicine: Evidence and Research will no longer consider meta-analyses for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信